يعرض 1 - 3 نتائج من 3 نتيجة بحث عن '"He, Cixin S"', وقت الاستعلام: 0.88s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial

    المؤلفون: Rha, Sun Young, Choueiri, Toni K., Matveev, Vsevolod B., Alyasova, Anna, Hong, Sung-Hoo, Gordoa, Teresa Alonso, Gurney, Howard, Bjarnason, Georg A., Buchler, Tomas, Pedrazzoli, Paolo, Takagi, Toshio, Park, Se Hoon, Lee, Jae Lyun, Perini, Rodolfo F., He, Cixin S., McKenzie, Jodi A., Eto, Masatoshi

    المصدر: Rha , S Y , Choueiri , T K , Matveev , V B , Alyasova , A , Hong , S-H , Gordoa , T A , Gurney , H , Bjarnason , G A , Buchler , T , Pedrazzoli , P , Takagi , T , Park , S H , Lee , J L , Perini , R F , He , C S , McKenzie , J A & Eto , M 2023 , ' Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal ....

    مصطلحات موضوعية: lenvatinib, pembrolizumab, renal cell carcinoma

    وصف الملف: application/pdf

    الإتاحة: https://doi.org/10.1002/ijc.34608Test
    https://researchers.mq.edu.au/en/publications/66479748-03c5-4433-acc3-27d9bfb80ff4Test
    https://research-management.mq.edu.au/ws/files/293053306/Publisher_version_open_access_.pdfTest
    http://www.scopus.com/inward/record.url?scp=85161699218&partnerID=8YFLogxKTest

    View record in BASE

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Lenvatinib Plus Everolimus or Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Study Design and Rationale

    المؤلفون: Grünwald, Viktor, Powles, Thomas, Choueiri, Toni K, Hutson, Thomas E, Porta, Camillo, Eto, Masatoshi, Sternberg, Cora N, Rha, Sun Young, He, Cixin S, Dutcus, Corina E, Smith, Alan, Dutta, Lea, Mody, Kalgi, Motzer, Robert J

    المصدر: Future Oncology ; volume 15, issue 9, page 929-941 ; ISSN 1479-6694 1744-8301

    الإتاحة: https://doi.org/10.2217/fon-2018-0745Test

    View record in BASE

    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).

    المؤلفون: Motzer, Robert J., Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E., Alekseev, Boris, Rha, Sun Young, Merchan, Jaime R., Goh, Jeffrey C., Kapoor, Anil, De Giorgi, Ugo, Melichar, Bohuslav, Hong, Sung-Hoo, Gurney, Howard, Rodriguez-Lopez, Karla, He, Cixin S., Okpara, Chinyere, McKenzie, Jodi, Choueiri, Toni K.

    المصدر: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p4502-4502, 1p


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث